We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Solifenacin in Multiple Sclerosis Patientswith Overactive Bladder: A Prospective Study.
- Authors
van Re, Farida; Heesakkers, John
- Abstract
Objective. To assess the efficacy and the effect on Qol of solifenacin for the treatment of OAB inMS patients. Patients and Methods. Thirty MS patients suffering from OAB were treated with solifenacin 5/10mg for 8 weeks. The first 4 weeks patients received solifenacin 5mg. At week 4 patients could request a dose increase to 10mg. The efficacy was evaluated at 8 weeks. Results. After 4 weeks of treatment, 28 patients reported acceptable or no side effects. 17 continued the study with the 10mg dosage, and 11 stayed on 5mg solifenacin. Two patients withdrew from the study due to side effects. Solifenacin 5/10mg for 8 weeks resulted in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement. Conclusions. Solifenacin is effective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).
- Subjects
MULTIPLE sclerosis; OVERACTIVE bladder; LONGITUDINAL method; QUALITY of life; ANTISPASMODICS; URINATION
- Publication
Advances in Urology, 2011, p1
- ISSN
1687-6369
- Publication type
Article
- DOI
10.1155/2011/834753